Nothing to cheer about Sun Pharma's FY20 guidance, says Research Delta Advisor

2019-05-29 2

Nimish Mehta, founder and director of Research Delta Advisor shared his take on Sun Pharmaceutical Industries' earnings.

Videos similaires

We continue to maintain the overall 14 to 16 percent guidance for FY20, says Prateek Aggarwal of HCL Tech

Infosys Hikes FY20 Revenue Guidance

Arvind Confident Of Meeting FY20 Guidance

Ashok Leyland on FY20-FY21 guidance

Nasscom on why they have held back FY20 guidance

Blue Star's Growth Guidance For FY20

HCL Tech Management Is Confident Of Delivering On Its FY20 Guidance

Will surpass earlier guidance of 40% growth for FY20, says Dixon Technologies

Parag Milk's Robust FY20 Revenue Guidance

JSW Steel Optimistic Of Meeting FY20 Sales Guidance

Web Analytics